178 related articles for article (PubMed ID: 32101903)
1. Beyond antibiotics for pulmonary nontuberculous mycobacterial disease.
Waterer G
Curr Opin Pulm Med; 2020 May; 26(3):260-266. PubMed ID: 32101903
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Interferon-γ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease.
Aoki A; Sakagami T; Yoshizawa K; Shima K; Toyama M; Tanabe Y; Moro H; Aoki N; Watanabe S; Koya T; Hasegawa T; Morimoto K; Kurashima A; Hoshino Y; Trapnell BC; Kikuchi T
Clin Infect Dis; 2018 Apr; 66(8):1239-1245. PubMed ID: 29126235
[TBL] [Abstract][Full Text] [Related]
3. Levels of anti-cytokine antibodies may be elevated in patients with pulmonary disease associated with non-tuberculous mycobacteria.
Kim K; Waterer G; Thomson R; Yang IA; Nashi N; Tan DB; Price P
Cytokine; 2014 Apr; 66(2):160-3. PubMed ID: 24508556
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection.
Valour F; Perpoint T; Sénéchal A; Kong XF; Bustamante J; Ferry T; Chidiac C; Ader F;
Emerg Infect Dis; 2016 Jun; 22(6):1124-1126. PubMed ID: 27192204
[No Abstract] [Full Text] [Related]
5. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review.
Hase I; Morimoto K; Sakagami T; Ishii Y; van Ingen J
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):308-315. PubMed ID: 28633901
[TBL] [Abstract][Full Text] [Related]
6. What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections?
Mortaz E; Moloudizargari M; Varahram M; Movassaghi M; Garssen J; Kazempour Dizagie M; Mirsaeidi M; Adcock IM
Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):100-109. PubMed ID: 29757583
[TBL] [Abstract][Full Text] [Related]
7. NK Cell-Derived IFN-γ Protects against Nontuberculous Mycobacterial Lung Infection.
Lai HC; Chang CJ; Lin CS; Wu TR; Hsu YJ; Wu TS; Lu JJ; Martel J; Ojcius DM; Ku CL; Young JD; Lu CC
J Immunol; 2018 Sep; 201(5):1478-1490. PubMed ID: 30061197
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections.
Chi CY; Lin CH; Ho MW; Ding JY; Huang WC; Shih HP; Yeh CF; Fung CP; Sun HY; Huang CT; Wu TS; Chang CY; Liu YM; Feng JY; Wu WK; Wang LS; Tsai CH; Ho CM; Lin HS; Chen HJ; Lin PC; Liao WC; Chen WT; Lo CC; Wang SY; Kuo CY; Lee CH; Ku CL
Medicine (Baltimore); 2016 Jun; 95(25):e3927. PubMed ID: 27336882
[TBL] [Abstract][Full Text] [Related]
9. Disseminated Mycobacterium gordonae and Mycobacterium mantenii infection with elevated anti-IFN-γ neutralizing autoantibodies.
Hase I; Morimoto K; Sakagami T; Kazumi Y; Ishii Y; van Ingen J
J Infect Chemother; 2015 Jun; 21(6):468-72. PubMed ID: 25735882
[TBL] [Abstract][Full Text] [Related]
10. Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report.
Tanaka S; Hoshino Y; Sakagami T; Fukano H; Matsui Y; Hiranuma O
BMC Infect Dis; 2019 May; 19(1):454. PubMed ID: 31117976
[TBL] [Abstract][Full Text] [Related]
11. '"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection.
Lake MA; Ambrose LR; Lipman MC; Lowe DM
BMC Med; 2016 Mar; 14():54. PubMed ID: 27007918
[TBL] [Abstract][Full Text] [Related]
12. Nontuberculous mycobacterial osteomyelitis.
Bi S; Hu FS; Yu HY; Xu KJ; Zheng BW; Ji ZK; Li JJ; Deng M; Hu HY; Sheng JF
Infect Dis (Lond); 2015; 47(10):673-85. PubMed ID: 25915177
[TBL] [Abstract][Full Text] [Related]
13. Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response.
Shamaei M; Mirsaeidi M
Infect Immun; 2021 Jul; 89(8):e0081220. PubMed ID: 34097459
[TBL] [Abstract][Full Text] [Related]
14. The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections.
Ghanavi J; Farnia P; Farnia P; Velayati AA
Int J Mycobacteriol; 2021; 10(4):349-357. PubMed ID: 34916451
[TBL] [Abstract][Full Text] [Related]
15. Autophagy and Host Defense in Nontuberculous Mycobacterial Infection.
Silwal P; Kim IS; Jo EK
Front Immunol; 2021; 12():728742. PubMed ID: 34552591
[TBL] [Abstract][Full Text] [Related]
16. Host immune response against environmental nontuberculous mycobacteria and the risk populations of nontuberculous mycobacterial lung disease.
Shu CC; Wu MF; Pan SW; Wu TS; Lai HC; Lin MC
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S13-S22. PubMed ID: 32451216
[TBL] [Abstract][Full Text] [Related]
17. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody.
Czaja CA; Merkel PA; Chan ED; Lenz LL; Wolf ML; Alam R; Frankel SK; Fischer A; Gogate S; Perez-Velez CM; Knight V
Clin Infect Dis; 2014 Mar; 58(6):e115-8. PubMed ID: 24336756
[TBL] [Abstract][Full Text] [Related]
18. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Kwon YS; Daley CL; Koh WJ
Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
[No Abstract] [Full Text] [Related]
19. Acquired and genetic host susceptibility factors and microbial pathogenic factors that predispose to nontuberculous mycobacterial infections.
Honda JR; Alper S; Bai X; Chan ED
Curr Opin Immunol; 2018 Oct; 54():66-73. PubMed ID: 29936307
[TBL] [Abstract][Full Text] [Related]
20. Immunodeficiency secondary to anticytokine autoantibodies.
Browne SK; Holland SM
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):534-41. PubMed ID: 20966748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
